Previous preclinical studies in the mdx mouse model of Duchenne muscular dystrophy targeting the myostatin pathway have utilized neutralizing antibodies, myostatin propeptide injection and recombinant adeno-associated virus (AAV) mediated expression of a myostatin inhibitor from multiple tissues [5], [13], [14]. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.